Analysis of Blood Spot 17-Hydroxyprogesterone Concentration According to Gestational Age and Birth Weight.
- Author:
Moon Soo KANG
1
;
Chung Hyun NAHM
;
Jong Weon CHOI
;
Yong Hoon JEON
;
Moon Whan IM
;
Chul Hoon LEE
;
Soo Hwan PAI
Author Information
1. Department of Clinical Pathology, Inha University College of Medicine, Incheon, Korea.
- Publication Type:Original Article
- Keywords:
17-Hydroxyprogesterone;
Premature infants;
Congenital adrenal hyperplasia;
Neonatal screening;
Cut-off limits;
Gestational age;
Birth weight
- MeSH:
17-alpha-Hydroxyprogesterone*;
Adrenal Hyperplasia, Congenital;
Birth Weight*;
Enzyme-Linked Immunosorbent Assay;
Gestational Age*;
Humans;
Infant;
Infant, Newborn;
Infant, Premature;
Mass Screening;
Neonatal Screening;
Parturition*;
Steroid 21-Hydroxylase
- From:Korean Journal of Clinical Pathology
2001;21(2):104-108
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: High levels of 17-hydroxyprogesterone (17-OHP) are frequently observed in premature infants without congenital adrenal hyperplasia. The purpose of this study is to set cut-off limits of 17-OHP on the basis of gestational age at birth and birth weight. METHODS: Blood spot 17-OHP concentrations were measured in 1,000 infants on the 3th day of life at Inha University Hospital. An enzyme-linked immunosorbent assay (ELISA) method (ICN Neoscreen ELISA 17-hydroxyprogesterone kit, ICN Pharmaceuticals. Inc., Japan) was used. The values obtained were analyzed with respect to birth weight and gestational age at birth in order to decide the appropriate cut-off limits in a neonatal mass screening for 21-hydroxylase deficiency. RESULTS: In the neonatal mass screening for CAH, the cut-off limits for determining the 17-OHP for recall, were decided as follows: (1) 57.65, 39.88, 33.52 ng/mL for gestational age at birth of 35 weeks or less, 36-37, and 38 weeks or more, respectively, and (2) 54.88, 43.86, 32.92 ng/mL for birth weight of 2.49 or less, 2.50-2.99, 3.00 kg or more, respectively. CONCLUSIONS: The cut-off limits on the basis of gestational age at birth and birth weight should be used in the screening for congenital adrenal hyperplasia. We believe that the false positive rate in premature infants can be reduced using this method.
